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Aims: To conduct a patient-level meta-analysis of the EDITION 1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine
300 U/ml (Gla-300) with insulin glargine 100 U/ml (Gla-100) in people with type 2 diabetes (T2DM) on basal and mealtime insulin, basal insulin and oral
antihyperglycaemic drugs, or no prior insulin, respectively.
Methods: The EDITION studies were multicentre, randomized, open-label, parallel-group, phase IIIa studies, with similar designs and endpoints.
A patient-level meta-analysis of the studies enabled these endpoints to be examined over 6months in a large population with T2DM (Gla-300, n= 1247;
Gla-100, n= 1249).
Results: No significant study-by-treatment interactions across studies were found, enabling them to be pooled. The mean change in glycated
haemoglobin was comparable for Gla-300 and Gla-100 [each −1.02 (standard error 0.03)%; least squares (LS) mean difference 0.00 (95% confidence
interval (CI) −0.08 to 0.07)%]. Annualized rates of confirmed (≤3.9mmol/l) or severe hypoglycaemia were lower with Gla-300 than with Gla-100 during
the night (31% difference in rate ratio over 6months) and at any time (24 h, 14% difference). Consistent reductions were observed in percentage of
participants with ≥1 hypoglycaemic event. Severe hypoglycaemia at any time (24 h) was rare (Gla-300: 2.3%; Gla-100: 2.6%). Weight gain was low
(<1 kg) in both groups, with less gain with Gla-300 [LS mean difference −0.28 kg (95% CI −0.55 to −0.01); p= 0.039]. Both treatments were well
tolerated, with similar rates of adverse events.
Conclusion: Gla-300 provides comparable glycaemic control to Gla-100 in a large population with a broad clinical spectrum of T2DM, with consistently
less hypoglycaemia at any time of day and less nocturnal hypoglycaemia.
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Introduction
Type 2 diabetes (T2DM) is a complex, heterogeneous disor-
der [1]. The requirement to initiate insulin therapy in people
with T2DM depends on behavioural and disease character-
istics, e.g. individual lifestyle and disease stage [2]. Initially,
people with T2DM often achieve glycaemic control without
insulin, by making lifestyle changes or by taking one or more
oral antihyperglycaemic drugs; however, as the disease pro-
gresses, exogenous insulin therapy is required inmany patients.
Often basal insulin therapy alone is the preferred initial insulin
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regimen, because it has a lower risk for inducing hypogly-
caemia and causes less weight gain compared with premixed
insulin or multiple daily injection therapy (basal plus bolus
therapy) [3]. In advanced disease stages, additional therapy (e.g.
with rapid-acting insulin or glucagon-like peptide-1 receptor
agonists) may be needed in order to effectively manage dis-
ease [2]. A basal insulin should therefore be effective across a
wide spectrum of disease stages, from insulin-naïve people to
those receiving combination therapy, with minimal disruption
to daily life.
The clinical development programme for new insulin
glargine 300U/ml (Gla-300) covers a broad range of T2DM
disease stages. Three phase IIIa studies compared the effi-
cacy and safety of Gla-300 with insulin glargine 100U/ml
(Gla-100) in differing populations of people with T2DM
[4–6]. Two of these studies enrolled high basal insulin users;
the first, EDITION 1, included participants with T2DM not
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adequately controlled with basal and mealtime insulin [4],
while EDITION 2 included participants who had previously
received basal insulin in combination with oral antihy-
perglycaemic drugs [5]. In EDITION 3, participants were
insulin-naïve, and had received only oral antihyperglycaemic
drugs [6].The results of these three studies showed that Gla-300
and Gla-100 provided comparable glycaemic control, along
with a lower risk of hypoglycaemiawithGla-300, over 6months
of treatment [4–6]. This is attributed to the more constant and
prolonged pharmacokinetic and pharmacodynamic profile of
Gla-300 compared with Gla-100 [7].
While the clinical characteristics of Gla-300 have been
described in the individual EDITION studies, it is important to
investigate whether these results are robust in a T2DM popu-
lation with a broader clinical spectrum, more closely reflecting
the patient spectrum in clinical practice. Similarities between
study endpoints and study designs for the three EDITION
studies have enabled a patient-level meta-analysis to be carried
out. The prespecified analysis included the EDITION 2 and
EDITION 3 studies only, but consistent design and results
allowed the pooling of all three studies, comprising a pooled
population of almost 2500 people. In the present paper, the
results of the patient-level meta-analysis of the three studies in
T2DM are reported, including measures of glycaemic control,
hypoglycaemia and body weight over 6months. The prespeci-
fied pooled analysis of the EDITION 2 and EDITION 3 studies
only is also reported to demonstrate consistency.
Research Design and Methods
Study Design and Participants
The prespecified pooled analysis included participants from
EDITION 2 and EDITION 3 only, because treatment with
rapid-acting insulin in EDITION 1 may have confounded
specificity of the results for basal insulin treatment; however,
the consistent study results suggested that a pooled analy-
sis should include all three studies. Therefore an additional
post-trial pooled analysis that also included participants from
EDITION 1 was performed. Data from both pooled analyses
are reported.
EDITION 1, 2 and 3 were multicentre, randomized,
open-label, two-arm, parallel-group, phase IIIa studies
(NCT01499082, NCT01499095, NCT01676220) that have
been described previously [4–6]. Protocols for all three studies
were approved by the appropriate ethics committees and the
studies were conducted according to Good Clinical Practice
and the Declaration of Helsinki. All participants provided
written, informed consent. The studies all included a 2-week
screening phase, a 6-month treatment period and a 6-month
safety extension period; data from the first 6-month treatment
period are reported here. All participants were≥18 years of age
with a diagnosis of T2DM (according to WHO criteria) [8].
Inclusion/exclusion criteria have been previously published
[4–6]; key criteria are shown in Table S1. In summary, in
EDITION 1, inclusion criteria included current basal therapy
with ≥42U/day of either Gla-100 or neutral protamine Hage-
dorn (NPH) insulin, together with prandial insulin therapy,
with or without metformin, for at least 1 year. In EDITION 2,
inclusion criteria included at least 6months on basal insulin
treatment (recent use within last 4 weeks of≥42U/day of either
Gla-100 or NPH insulin in combination with oral antihyper-
glycaemic drugs). In EDITION 3, participants were required to
have used oral antihyperglycaemic drugs for at least 6months
before screening and were insulin-naïve. Exclusion criteria
included glycated haemoglobin (HbA1c) <7.0% for all three
studies, HbA1c >10.0% for EDITION 1 and 2, and >11.0% for
EDITION 3.
Treatment
Participants in all studies were randomized (1 : 1) to receive
once-daily subcutaneous injections of either Gla-300 (Sanofi,
Paris, France; using a modified SoloSTAR® pen-injector in
EDITION 1 and 2, and a modified Tactipen® injector in
EDITION 3) or Gla-100 [Lantus® (Sanofi) using a SoloSTAR®
pen]. The accuracy of the modified version of the SoloSTAR®
device was adequate for use with Gla-300 at doses above
39U. The modified Tactipen® used in EDITION 3 allowed
smaller increment steps (1.5U) compared with the modified
SoloSTAR® pen (3U), to enable dosing for an insulin-naïve
population with a wide range of insulin requirements. All
participants were titrated to a fasting self-monitored plasma
glucose (SMPG) target of 4.4–5.6mmol/l (80–100mg/dl).
Endpoints of Patient-level Meta-analysis
Both pooled analyses were carried out for the following efficacy
endpoints: change in HbA1c from baseline to month 6; pro-
portion of participants with HbA1c <7.0% (<53mmol/mol) at
month 6; change in average pre-injection SMPG from baseline
to month 6; and change in laboratory-measured fasting plasma
glucose from baseline to month 6.
Prespecified safety and tolerability endpoints included
percentages of participants having at least one nocturnal
(00:00–05:59 hours) hypoglycaemic event or hypoglycaemic
event at any time of day (24 h) and annualized rates (events per
participant-year), by study period, and the cumulative mean
number of hypoglycaemic events per participant. The prespec-
ified definition of the nocturnal window (00:00–05:59 hours)
was chosen to exclude potential confounders relating to day-
time activities and meal intake. All hypoglycaemic events were
categorized according to the American Diabetes Association
definitions [9]: (i) severe hypoglycaemia (an event requiring
the assistance of another person to actively administer carbohy-
drate, glucagon or other resuscitative actions); (ii) documented
symptomatic hypoglycaemia [an event during which typical
symptoms of hypoglycaemia are confirmed by a measured
plasma glucose concentration of ≤3.9mmol/l (≤70mg/dl)];
(iii) and asymptomatic hypoglycaemia confirmed by a
measured plasma glucose concentration of ≤3.9mmol/
l (≤70mg/dl). For the main analysis of hypoglycaemic
outcomes, the confirmed (with or without symptoms) and
severe categories were combined.
The pooled analysis of EDITION 1, 2 and 3 also evaluated
insulin dose, variability of pre-injection SMPG, change in body
weight and adverse events.
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Data Analysis and Statistics
Methods were consistent with those of the EDITION studies
and have been reported previously [3–5]. Change in HbA1c,
and all other efficacy measures except insulin dose, was
analysed using a mixed model for repeated measurements
(MMRM). Insulin dose was measured descriptively. The per-
centage of participants reporting ≥1 hypoglycaemic event was
analysed using the Cochran–Mantel–Haenszel method. The
annualized rate of hypoglycaemia (events per participant-year)
was analysed using an overdispersed Poisson regressionmodel.
Cumulative mean number of hypoglycaemic events by par-
ticipant was analysed using Nelson–Aelen estimates. The
percentage of participants with ≥1 event and the annualized
rates of hypoglycaemia were also examined by age subgroup
(>65 years of age vs ≤65 years of age); subgroup-by-treatment
interaction was calculated based on a logistic model with
subgroup, treatment, randomization strata of screening HbA1c
(<8.0 and ≥8.0%) and the interaction subgroup-by-treatment
as fixed effects. Body weight was assessed using an analysis of
covariance (ancova)model, from baseline to last on-treatment
value. Adverse events were analysed descriptively. For each
endpoint, homogeneity of treatment effect across all three
studies was assessed.
Efficacy endpoints used the modified intention-to-treat
(mITT) population, defined as all randomized participants
who received at least one dose of study drug and had both
a baseline and ≥1 post-baseline assessment. If a participant
discontinued treatment prematurely, or for all participants
rescued during the 6-month on-treatment period (EDITION 2
and 3 only), time windows were applied to retrieve assessments
performed at premature end-of-treatment and pre-rescue visits
for the MMRM analyses. The safety population included all
participants randomized and exposed to≥1 dose of study drug.
Results
Study Population
Of the 2496 participants included in the pooled analysis of
all three EDITION T2DM studies, 1247 were randomized to
Gla-300 and 1249were randomized toGla-100.ThemITTpop-
ulation included 1239 and 1235 participants receiving Gla-300
and Gla-100, respectively. Baseline characteristics from the
individual study populations and the pooled analysis popula-
tion (all three studies) are shown in Table 1. Baseline character-
istics of the EDITION 2 and EDITION 3 pool are reported in
Table S2.
Homogeneity of Treatment Effect
The study-by-treatment interaction for each endpoint was
found to be non-significant.
Glycaemic Control
In the pooled dataset of all three studies, the mean decrease
in HbA1c level was similar in the two treatment groups
(Figure 1A).The least squares (LS) mean [standard error (s.e.)]
change in HbA1c from baseline to month 6 was comparable Ta
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Figure 1. (A) Glycated haemoglobin (HbA1c), (B) Laboratory-measured fasting plasma glucose (FPG), (C) Insulin dose [modified intention-to-treat
(mITT) population and (D) body weight (safety population) by visit during the 6-month treatment period for pooled analysis of all three studies. Gla-100,
insulin glargine 100U/ml; Gla-300, insulin glargine 300U/ml; LS, least squares; BL, baseline;M,month; s.e, standard error;W,week. LOV, last on-treatment
value defined as the last measurement made prior to or on the day of the last investigational product intake during the main 6-month on-treatment period.
for Gla-300 and Gla-100 [each −1.02 (0.03)%; LS mean dif-
ference 0.00, 95% confidence interval (CI) −0.08 to 0.07%].
The proportion of participants who reached target HbA1c after
6months of treatment was similar in both treatment groups;
449 participants (36.2%) on Gla-300 and 438 participants
(35.5%) on Gla-100 attained an HbA1c target of <7.0%.
Laboratory-measured fasting plasma glucose decreased
in both groups (Figure 1B); LS mean (s.e.) change at
month 6 was −2.04 (0.07)mmol/l with Gla-300 and −2.26
(0.07)mmol/l with Gla-100 (LS mean difference 0.21, 95% CI
0.03–0.40mmol/l). Average pre-injection SMPGalso decreased
in both treatment groups, and reductions from baseline to
month 6 were similar for Gla-300 and Gla-100 [LS mean
(s.e.) change −1.43 (0.08) and −1.34 (0.08)mmol/l; LS mean
difference −0.09, 95% CI −0.31 to 0.14mmol/l]. There was
also no between-treatment difference in the variability of
pre-injection SMPG at month 6; LS mean (s.e.) at month 6 was
20.0 (0.32)% with Gla-300 and 20.0 (0.33)% with Gla-100 (LS
mean difference 0.02%, 95% CI −0.89 to 0.93).
Similar results for glycaemic control were observed in the
pooled dataset of EDITION 2 and EDITION 3 (Table S3).
Hypoglycaemia
In the pooled analysis of EDITION 1, 2 and 3, over the
6-month treatment period, the cumulative number of con-
firmed [≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemic
events per participant was lower with Gla-300 compared with
Gla-100 at any time of day (24 h; Figure 2A). The annualized
rate (events per participant-year) of confirmed [≤3.9mmol/l
(≤70mg/dl)] or severe hypoglycaemia at any time of day
(24 h) over the 6-month study period was 15.22 with Gla-300
and 17.73 with Gla-100 (rate ratio 0.86, 95% CI 0.77–0.97;
p= 0.0116), corresponding to a relative difference of 14% in
favour of Gla-300.
The cumulative mean number of nocturnal confirmed
[≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemic events
was lower with Gla-300 than Gla-100 (Figure 2B). Similarly,
annualized rates of nocturnal events over the 6-month study
period were lower with Gla-300 (2.10 vs 3.06, rate ratio 0.69,
95% CI 0.57–0.84; p= 0.0002), showing a relative difference in
rate of 31% in favour of Gla-300.
When analysed by study period, the reduction in annualized
rate with Gla-300 compared with Gla-100 was even apparent
during the first 8 weeks of treatment, as well as during the
maintenance period (week 9 to month 6; Figure 3A, B).
The distribution of annualized rates of confirmed
[≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemic events
over 24 h is reported in Figure 4. A lower rate of hypoglycaemia
was shown during the night and beyond the predefined noctur-
nal period (00:00–05:59 hours) with Gla-300 compared with
Gla-100. Events were most frequently reported between 06:00
and 14:00 hours [4777 (8.14 events per participant-year) in the
Gla-300 group and 5925 (10.13 events per participant-year)
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Figure 2. Cumulative mean number of confirmed [≤3.9mmol/l
(≤70mg/dl)] or severe hypoglycaemic events (A) at any time of day (24 h)
and (B) during the night (00:00–05:59 hours) for pooled analysis of all
three studies (safety population). Gla-100, insulin glargine 100U/ml;
Gla-300, insulin glargine 300U/ml.
in the Gla-100 group, corresponding to a reduction of 20%
in favour of Gla-300], and particularly between 06:00 and
10:00 hours.
Reductions in the percentage of participants experiencing
≥1 confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypogly-
caemic event at any time of day (24 h) and during the night
with Gla-300 compared with Gla-100 were consistent with the
annualized rates (Figure 3A, B). The number of participants
who would need to be treated with Gla-300 in order to prevent
1 participant having a confirmed [≤3.9mmol/l (≤70mg/dl)]
or severe hypoglycaemic event compared with treatment with
Gla-100 was 16.
Rates and percentages of participants with confirmed
[≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemic events
were comparable between those ≥65 years of age and those
<65 years and no significant heterogeneity of treatment effect
was observed (all p> 0.05).
Consistent results for confirmed [≤3.9mmol/l (≤70mg/dl)]
or severe hypoglycaemia were observed in the pooled analysis
of the EDITION 2 and EDITION 3 studies (Figures S1 and S2).
Other Categories of Hypoglycaemia
Over the 6-month treatment period, the annualized rate of
documented [≤3.9mmol/l (≤70mg/dl)] symptomatic hypo-
glycaemic events was lower for Gla-300 compared with
Gla-100, both at any time of day (24 h; Figure 3A) and
during the night (Figure 3B). A consistently lower percent-
age of participants reported ≥1 documented [≤3.9mmol/l
(≤70mg/dl)] symptomatic hypoglycaemic event with Gla-300
versus Gla-100 (Figure 3A, B).
Similar results were observed in the EDITION 2 and 3
pooled analysis (Figures S1 and S2). Consistent reductions were
shown with Gla-300 compared with Gla-100 for both con-
firmed or severe and documented symptomatic hypoglycaemia
when the stricter threshold of <54mg/dl (<3.0mmol/l) was
applied (Table S4).
Severe Hypoglycaemia
Severe hypoglycaemia was rare in both treatment groups. In the
pooled analysis of all three studies, the number of participants
with ≥1 event at any time of day (24 h) was 28 (2.3%) with
Gla-300 and 33 (2.6%) with Gla-100 (relative risk 0.85, 95% CI
0.52–1.39); there were 0.11 events per participant-year in both
groups (rate ratio 0.98, 95% CI 0.51–1.86; Table S4).
Insulin Dose
Basal insulin dose increased in both treatment groups over the
6-month study period (Figure 1C). The mean (standard devi-
ation) basal insulin dose at month 6 was 0.85 (0.36)U/kg/day
withGla-300 and 0.76 (0.32)U/kg/daywithGla-100, represent-
ing a 12% higher dose with Gla-300.
Body Weight
There was a slight weight gain with Gla-300 and Gla-100
[LS mean (s.e.) change 0.51 (0.10) and 0.79 (0.10) kg, respec-
tively, in the pooled analysis of EDITION 1, 2 and 3], but
with less weight gain in Gla-300 treated participants (LS
mean difference −0.28, 95% CI −0.55 to −0.01; p= 0.039;
Figure 1D).
Adverse Events
No between-treatment differences in safety profile were iden-
tified, with similar rates of adverse events reported across
all three studies. Treatment-emergent adverse events (TEAEs)
were reported by 712 (57.3%) participants in the Gla-300 group
and 669 (53.7%) participants in the Gla-100 group. The most
common TEAEs were infections and infestations, nervous sys-
tem disorders, gastrointestinal disorders, musculoskeletal and
connective tissue disorders, and general disorders and admin-
istration site conditions.
Injection site reactions were reported for 30 (2.4%) partici-
pants in the Gla-300 group and 39 (3.1%) participants in the
Gla-100 group. Serious TEAEs were reported by 65 (5.2%)
and 62 (5.0%) participants in the Gla-300 and Gla-100 groups,
respectively (Table S5). Overall, 17 (1.4%) and 16 partici-
pants (1.3%) discontinued treatment because of a TEAE in the
Gla-300 and Gla-100 groups, respectively, while 4 participants
(0.3%) in the Gla-300 group and 3 (0.2%) in the Gla-100 had
a TEAE leading to death. No deaths were considered related to
study medication. Anti-insulin antibody findings were similar
between treatment groups and across the three studies.
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                      Annualized rates           % of participants 
Confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia
Documented symptomatic hypoglycaemia (≤3.9 mmol/l [≤70 mg/dl])
B
Gla-300 Gla-100Favours Gla-300 Gla-100Favours
                      Annualized rates           % of participants 
Rate 95% CI Relative 95% CI
ratio  risk
Rate 95% CI Relative 95% CI
ratio  risk
Confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia
Documented symptomatic hypoglycaemia (≤3.9 mmol/l [≤70 mg/dl])
BL to W8 0.58 0.47 to 0.73 0.69 0.58 to 0.81
W9 to M6 0.75 0.60 to 0.94 0.80 0.71 to 0.91
BL to M6 0.69 0.57 to 0.84 0.75 0.68 to 0.83
BL to W8 0.54 0.42 to 0.70 0.61 0.50 to 0.75
W9 to M6 0.66 0.53 to 0.84 0.84 0.72 to 0.97
BL to M6 0.62 0.51 to 0.76 0.75 0.66 to 0.85
BL to W8 0.77 0.68 to 0.89 0.83 0.77 to 0.89
W9 to M6 0.91 0.80 to 1.03 0.92 0.86 to 0.98
BL to M6 0.86 0.77 to 0.97 0.91 0.87 to 0.96
BL to W8 0.73 0.62 to 0.87 0.78 0.70 to 0.86
W9 to M6 0.91 0.78 to 1.07 0.93 0.85 to 1.01
BL to M6 0.85 0.74 to 0.97 0.88 0.82 to 0.94
Annualized rates % of participants
Annualized rates % of participantsA
Gla-300 Gla-100Favours
0.3 Rate ratio 3 0.3 Relative risk 3
0.3 Rate ratio 3 0.3 Relative risk 3
Gla-300 Gla-100Favours
Figure 3. Annualized rates and percentage of participants with ≥1 hypoglycaemic event (A) at any time of day (24 h) and (B) during the night
(00:00–05:59 hours) for pooled analysis of all three studies (safety population). Gla-100, insulin glargine 100U/ml; Gla-300, insulin glargine 300U/ml;
CI, confidence interval; BL, baseline; W, week; M, month.
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Figure 4. Annualized rates (events per participant-year) of confirmed
[≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemia during 6months of
treatment by time of the day for pooled analysis of all three studies (safety
population). Gla-100, insulin glargine 100U/ml; Gla-300, insulin glargine
300U/ml.
Discussion
In this large, broad population of participants with T2DM,
Gla-300 was shown to be as effective as Gla-100 in improving
glycaemic control over 6months. In addition, Gla-300 resulted
in a reduction in hypoglycaemic events at any time of day (24 h),
as well as during the night, and slightly lower weight gain com-
pared with Gla-100. Results were consistent in the prespecified
pooled analysis where participants from the EDITION 1 study
using rapid-acting insulin analogues were excluded.These find-
ings were made possible through the similar study designs
of the three phase IIIa EDITION studies [4–6], and con-
firm the consistency of the findings across these individual
studies, which also showed comparable glycaemic control and
a lower risk of hypoglycaemia with Gla-300 compared with
Gla-100.
In the overall pooled analysis, the relative difference in rate
of confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypogly-
caemia at any time of day (24 h) in favour of Gla-300 was
14% over the entire 6months of treatment. The corresponding
difference was 5% in EDITION 1 (probably as a result of the
use of rapid-acting insulin analogues) [4], but was higher for
EDITION 2 and 3 (23 and 25%) [5,6], suggesting that the
pooled analysis results were mainly driven by the size of the
reductions observed in EDITION 2 and EDITION 3 for that
period. The reductions in risk of participants experiencing
≥1 hypoglycaemic event seen in the pooled analysis were
consistent with the annualized rates, although the contribution
of each individual study to these findings appeared to be
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similar (relative risk reductions of 7, 10 and 12% were seen in
EDITION 1, 2 and 3, respectively, over the 6-month treatment
period) [4–6].
Even greater relative differences in annualized rate of con-
firmed or severe hypoglycaemia in favour of Gla-300 were
observed during the night (31% during the entire 6months of
treatment). Corresponding differences for the 6-month period
were 25, 48 and 2% in EDITION 1, 2 and 3, respectively,
suggesting that the reduction seen in the pooled analysis was
mainly driven by the findings of EDITION 1 and 2. Again, per-
centages of participants experiencing ≥1 hypoglycaemic event
during the night were consistent with the annualized rates, and
were supported by all three of the individual studies (reduc-
tions of 22, 29 and 24% over the 6-month treatment period, for
EDITION 1, 2 and 3, respectively) [4–6].
In the pooled analysis of all three studies, reductions in annu-
alized rate even occurred during the first 8 weeks of the study,
when most of the insulin dose increase took place (relative
reductions of 23% in the first 8 weeks and 9% in the mainte-
nance period for anytime hypoglycaemia and 42% in the first
8 weeks comparedwith 25% in themaintenance period for noc-
turnal hypoglycaemia). Concern over hypoglycaemia is often a
barrier to effective dose adjustment [10–12]. The lower risk of
hypoglycaemia during the titration period with Gla-300 could
therefore afford a smoother start to the therapy and lead to
improved confidence in increasing the dose for both physi-
cians and people with diabetes, allowing optimum doses to be
reached sooner.
The variations seen between the individual EDITION studies
reflect the differences in the populations studied; for example,
participants in EDITION 3 had fewer characteristics that are
predictive of hypoglycaemia [13], compared with EDITION 1
and 2, as they were insulin-naïve, probably retaining greater
endogenous insulin secretion, andwith a shorter diabetes dura-
tion [4–6]. Despite these variations, the benefits of Gla-300 over
Gla-100 are clearly apparent in the large pooled analysis popu-
lation representing a broad spectrum of T2DM disease stages.
These findings suggest that the benefits of Gla-300 observed in
higher basal insulin users in EDITION 1 and 2 are translatable
to people with less advanced disease.
Over the course of 24 h, the period during which the most
confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemic
events were reported was between 06:00 and 08:00 hours, with
fewer events for Gla-300 compared with Gla-100, showing
that the benefits of Gla-300 over Gla-100 extend beyond the
predefined ‘nocturnal’ period (00:00–05:59 hours). Indeed, a
difference in favour of Gla-300 was apparent up to 14:00 hours.
Daytime hypoglycaemia interferes with daily activities such
as working, attending school or driving, which causes serious
social disruptions for people with diabetes [14]. The reduction
in hypoglycaemia seen with Gla-300 during the morning and
early afternoon may therefore help to lessen the impact of dia-
betes on daily activities. This effect may be attributable to the
more stable and prolonged pharmacokinetic and pharmacody-
namic profiles of Gla-300 compared with Gla-100 [7], which
suggests potential for more people to achieve good glycaemic
control with once-daily injection. Once-daily administration
coupled with a reduced rate of hypoglycaemia may help to
reduce the burden of diabetes disease management, improv-
ing adherence to insulin regimens and increasing treatment
persistence [11]. This could ultimately improve long-term
blood glucose control for those people with diabetes who are
failing to achieve glycaemic targets with current treatment
options.
Severe hypoglycaemia was rare in both treatment groups
in the pooled population of all three EDITION studies. The
annualized rates of 0.11 events per participant-year are similar
to those reported in observational studies in T2DM [15,16],
which range from 0.1 to 0.2 events per participant-year.
Reductions in the rate of hypoglycaemia compared with
Gla-100 have also been reported with other longer-acting
basal insulins. In a meta-analysis of five studies in T2DM, of
26–52weeks’ duration, differences in annualized rate ratios of
confirmed hypoglycaemia in favour of insulin degludec com-
pared with Gla-100 were reported, both at any time (17%) and
during the night (32%) [17]. Although these are consistent with
the 14 and 31% reductions seen for confirmed (≤3.9mmol/l)
or severe hypoglycaemia in the present analysis, it should be
noted that in the insulin degludec studies, confirmed hypogly-
caemia was defined as episodes confirmed by a plasma glucose
of <3.1mmol/l (<56mg/dl), or severe hypoglycaemia. Addi-
tionally, participantswere titrated to a different glycaemic target
[4.0 to <5.0mmol/l (>70 to <90mg/dl)] compared with the
EDITION studies, and the study populations and characteris-
tics of the participants were also different. Finally, other mea-
sures of hypoglycaemia, such as percentage of participants with
one or more event, are not reported for the insulin degludec
pooled analysis.These differencesmake it difficult to draw com-
parisons between these twometa-analyses, or with pooled anal-
yses for other insulins such as Gla-100 [18], for which the data
reported also differ from the present analysis.
Basal insulin dose increased in both treatment groups over
the 6-month study period, particularly in the first 12weeks
of treatment. The basal insulin dose in the Gla-300 group at
6months was 12% greater than in the Gla-100 group, a find-
ing that has been consistently observed in all three EDITION
studies. The cause of the difference in insulin dosage is cur-
rently speculative. Metabolite M1 is the main active molecule
circulating after injection of both Gla-300 and Gla-100 [19];
however, an effect at the subcutaneous depot seems likely. It is
possible that a longer residence time for Gla-300 in the subcu-
taneous space (consistent with the more stable and prolonged
pharmacokinetic and pharmacodynamic profiles of Gla-300 vs
Gla-100 [7]) might lead to an increase of enzymatic inactiva-
tion by tissue peptidases at the injection site. This observation
suggests a somewhat lower bioavailability of Gla-300 compared
with Gla-100.
Despite the higher dose of Gla-300 versus Gla-100, compa-
rable glycaemic control was achieved with less hypoglycaemia.
Along with these benefits in hypoglycaemia, participants who
receivedGla-300 had less weight gain comparedwith thosewho
received Gla-100. The reason for this is unknown, and further
analyses are warranted.
While the benefits of Gla-300 over Gla-100 have been
demonstrated in the individual EDITION studies, there
was some variation in baseline characteristics between the
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populations, which could be considered a limitation of this
pooled analysis; however, the size of the population increases
the validity of the results, and overcomes in part a limitation
of the individual EDITION studies – the generalizability of
the results to other populations with T2DM, as the charac-
teristics of the population have been broadened by pooling.
Other populations, such as different ethnic groups, still need
to be considered. The pooled analysis is also strengthened
by the similarities between the EDITION studies in terms of
design. Limitations of the design for these studies include the
open-label nature of the treatment and the short duration.
Additionally, the pooled analysis of all three studies was not
pre-planned; however, the results are supported by the pre-
specified analysis of the EDITION 2 and 3 studies only. The
subgroup analyses by age group are post hoc and should be
interpreted with caution.
In conclusion, Gla-300, in a broad population of almost 2500
people with T2DM, provides comparable glycaemic control to
that provided by Gla-100, with less hypoglycaemia at any time
of day (24 h), and a more pronounced reduction in hypogly-
caemia during the night, and during the first 8 weeks.
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